Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Short Interest Update

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 14,200 shares, a decline of 68.7% from the October 31st total of 45,400 shares. Based on an average trading volume of 119,900 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the shares of the company are sold short.

Wall Street Analyst Weigh In

ONCT has been the topic of a number of analyst reports. StockNews.com started coverage on Oncternal Therapeutics in a report on Wednesday. They issued a “hold” rating on the stock. HC Wainwright dropped their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Securities reissued a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Stock Performance

NASDAQ ONCT remained flat at $0.75 during trading hours on Wednesday. 146,592 shares of the company were exchanged, compared to its average volume of 41,696. The business’s fifty day moving average price is $1.33 and its 200-day moving average price is $4.71. Oncternal Therapeutics has a 12-month low of $0.62 and a 12-month high of $13.14. The company has a market cap of $2.21 million, a PE ratio of -0.06 and a beta of 1.33.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.